This study aims to analyze the effects of long-acting granulocyte colony stimulating factor (G-CSF) on the prevention febrile neutropenia (FN) in gynecologic cancer patients. Patients all accepted platinum-based chemotherapy 3-4 weeks once per course. The primary end is the incidence of FN in every course of chemotherapy. After the chemotherapy, patients accepted long-acting G-CSF and/or short-acting G-CSF. The secondary ends include: the incidences of myelosuppression, doses of G-CSF and its expenses, visits to outpatient and emergency clinics, adverse events related to G-CSF.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
100
Long-acting G-CSF will be given 48 hours after the chemotherapy. A supplement of short-acting G-CSF will be given as required.
Short-acting G-CSF will be given as required 24 hours after the chemotherapy.
Lei Li
Beijing, Beijing Municipality, China
RECRUITINGIncidence of febrile neutropenia
Incidence of febrile neutropenia in each course
Time frame: One year
Incidences of grade 3/4 myelosuppression
Incidences of grade 3/4 myelosuppression in each course
Time frame: One year
Times of visits to outpatient and emergency clinics
Visits to outpatient and emergency clinics in each course
Time frame: One year
Doses of G-CSF
Doses of G-CSF administrated in each course
Time frame: One year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.